Hrp conjugated secondary antibodies antimouse and antirabbit

Manufactured by GE Healthcare

Sourced in United Kingdom

HRP-conjugated secondary antibodies (antimouse and antirabbit) are laboratory reagents used in various immunoassay techniques. They consist of secondary antibodies that are conjugated to the enzyme horseradish peroxidase (HRP). These reagents are used to detect and amplify the signal from primary antibodies that have bound to their target analytes in a sample.

Automatically generated - may contain errors

Lab products found in correlation

Mouse anti gapdh, by Santa Cruz Biotechnology (2 mentions) Phospho ser pkc substrate, by Cell Signaling Technology (2 mentions) Protease and phosphatase inhibitor cocktail sets, by Roche (2 mentions) Phospho akt ser473, by Cell Signaling Technology (2 mentions) Immobolin pvdf membranes, by Merck Group (2 mentions) Akt antibody, by Cell Signaling Technology (1 mentions) Puromycin, by Merck Group (1 mentions) L 685 458, by Merck Group (1 mentions) β actin antibody, by Merck Group (1 mentions) App c terminal antibody a8717, by Merck Group (1 mentions)

Spelling variants of this product

HRP-conjugated antibodies (19 citations)

4 protocols using hrp conjugated secondary antibodies antimouse and antirabbit

Cardiomyocyte Protein Expression Analysis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cardiomyocytes were lysed in buffer (150 mM NaCl, 20 mM Tris, pH 7.4, 1 mM EDTA, 1% Triton X-100) containing protease and phosphatase inhibitor cocktail sets (Roche, UK) and harvested as previously described.
17 (link)
Equal amounts of protein (15 µg/sample) were resolved by electrophoresis on 10% Tris-glycine gels, transferred onto Immobolin PVDF membranes (Millipore), blocked and probed with specific antibodies: Phospho-(Ser) PKC substrate, phospho-Erk1/2, (Thr202/Tyr204), Erk1/2, phospho-Akt, (Ser 473), and Akt antibodies (all 1:1,000 dilution) were from Cell Signaling Technology (Massachusetts, United States) and mouse–anti-GAPDH (1:2,000 dilution) was from Santa Cruz Biotechnology (Heidelberg, Germany). HRP-conjugated secondary antibodies (antimouse and antirabbit, both 1:10,000 dilution) were from GE Healthcare (Buckinghamshire, UK).

Walsh T.G, & Poole A.W. (2017). Platelets Protect Cardiomyocytes from Ischemic Damage. TH Open: Companion Journal to Thrombosis and Haemostasis, 1(1), e24-e32.

+ Open protocol

+ Expand

Quantifying APP and Ubiquilin-1 Interactions

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

L-685,458 and puromycin were purchased from Sigma. β-Actin antibody (1:10,000) was purchased from Sigma. The APP C-terminal antibody (A8717; 1:1,000) was purchased from Sigma. The ubiquilin-1 antibody (1:160) was purchased from Zymed. The HRP-conjugated secondary antibodies (anti-mouse and anti-rabbit) (1:10,000) were purchased from GE. The plasmids APP-Gal4, Gal4-UAS-luciferase (encoding firefly luciferase) were kindly provided from Dr. Thomas Südof, and have been described (Cao and Sudhof, 2001 (link)). The previously reported ubiquilin-1 expressing plasmid was constructed from the pCMV vector and was kindly provided by Dr. Mervyn J. Monteiro (Mah et al., 2000 (link)).

Zhang C., Inamdar S.M., Swaminathan S., Marenda D.R, & Saunders A.J. (2022). Association of the Protein-Quality-Control Protein Ubiquilin-1 With Alzheimer’s Disease Both in vitro and in vivo. Frontiers in Neuroscience, 16, 821059.

+ Open protocol

+ Expand

Cardiomyocyte Western Blot Analysis

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cardiomyocytes were lysed in buffer (150 mM NaCl, 20 mM Tris pH 7.4, 1 mM EDTA, 1% Triton X-100) containing protease and phosphatase inhibitor cocktail sets (Roche, UK) and harvested as previously described(17 (link)). Equal amounts of protein (15 μg/sample) were resolved by electrophoresis on 10% Tris-glycine gels, transferred onto Immobolin^® PVDF membranes (Millipore), blocked and probed with specific antibodies: Phospho-(Ser) PKC substrate, phospho-Erk1/2, (Thr202/Tyr204), Erk1/2, phospho-Akt, (Ser 473), and Akt antibodies (all 1:1000 dilution) were from Cell Signaling Technology (MA, USA) and mouse-anti GAPDH (1:2000 dilution) was from Santa Cruz Biotechnology (Heidelberg, Germany). HRP-conjugated secondary antibodies (anti-mouse and anti-rabbit, both 1:10,000 dilution) were from GE Healthcare (Buckinghamshire, UK).

Walsh T.G, & Poole A.W. (2017). Platelets Protect Cardiomyocytes from Ischemic Damage. TH Open: Companion Journal to Thrombosis and Haemostasis, 1(1), e24-e32.

+ Open protocol

+ Expand

Quantitative Protein Analysis using SDS-PAGE

Check if the same lab product or an alternative is used in the 5 most similar protocols

Total protein concentrations were determined using a BCA™ protein assay kit (Pierce, part of Thermo Fisher Scientific, Rockford, USA). Proteins of tissue homogenates were separated by SDS-PAGE using 20 μg total protein per lane. After blotting, membranes were blocked with 1% BSA and initially incubated overnight with primary antibody against α-SMA (1:1000). Blots were then stripped (24 mM glycine, 2% SDS, aqua dest, pH 2.0) at 65 °C, blocked with 1% BSA, and incubated overnight with primary antibody against GAPDH as a loading control (1:1500, Biomol, Hamburg, Germany). HRP-conjugated secondary antibodies (anti-mouse and anti-rabbit 1:10,000, GE Healthcare, Buckinghamshire, UK) were used as detection antibodies. Target proteins were visualized and quantified by Fusion Capt Advance FX7 detection software (Vilber Lourmat GmbH, Eberhardzell, Germany).

Hofrichter J., Sempert K., Kerkhoff C., Breitrück A., Wasserkort R, & Mitzner S. (2022). Phosphate restriction using a processed clay mineral reduces vascular pathologies and microalbuminuria in rats with chronic renal failure. BMC Nephrology, 23, 162.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!